BidaskClub upgraded shares of Viking Therapeutics (NASDAQ:VKTX) from a buy rating to a strong-buy rating in a research note issued to investors on Wednesday morning.
Several other research firms have also issued reports on VKTX. Maxim Group restated a buy rating and issued a $8.00 target price on shares of Viking Therapeutics in a report on Friday, February 2nd. ValuEngine lowered shares of Viking Therapeutics from a hold rating to a sell rating in a report on Friday, December 1st. Roth Capital assumed coverage on shares of Viking Therapeutics in a report on Tuesday, November 21st. They issued a buy rating and a $5.00 target price for the company. Finally, HC Wainwright restated a buy rating and issued a $7.00 target price on shares of Viking Therapeutics in a report on Friday, November 10th. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of Buy and an average price target of $7.00.
Shares of Viking Therapeutics (VKTX) opened at $6.35 on Wednesday. The stock has a market cap of $227.44 and a PE ratio of -7.47. Viking Therapeutics has a twelve month low of $0.88 and a twelve month high of $7.15.
A number of institutional investors and hedge funds have recently made changes to their positions in VKTX. Virtu KCG Holdings LLC bought a new stake in Viking Therapeutics during the 2nd quarter valued at about $124,000. Sabby Management LLC bought a new stake in Viking Therapeutics during the 2nd quarter valued at about $525,000. Sphera Funds Management LTD. bought a new stake in Viking Therapeutics during the 3rd quarter valued at about $554,000. Citadel Advisors LLC bought a new stake in Viking Therapeutics during the 3rd quarter valued at about $108,000. Finally, Creative Planning lifted its holdings in Viking Therapeutics by 600.0% during the 4th quarter. Creative Planning now owns 70,000 shares of the biotechnology company’s stock valued at $284,000 after buying an additional 60,000 shares in the last quarter. Institutional investors own 5.86% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Viking Therapeutics (VKTX) Upgraded at BidaskClub” was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://sportsperspectives.com/2018/02/10/viking-therapeutics-vktx-upgraded-at-bidaskclub.html.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.